WEBULL
News
VANI
1.170
-6.40%
-0.080
Weekly Report: what happened at VANI last week (0202-0206)?
Weekly Report · 3d ago
Weekly Report: what happened at VANI last week (0126-0130)?
Weekly Report · 02/02 09:04
Vivani’s Cortigent presents 6-year results for Orion system at NANS 2026
TipRanks · 01/29 12:41
Vivani's Brain Implant Helps Blind Patients See Light And Movement In 6-Year Study
Benzinga · 01/29 12:35
Cortigent Reports Promising Six-Year Results for Orion Visual Prosthesis
Reuters · 01/29 12:30
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
Barchart · 01/29 06:30
Major Insider Move Signals Growing Confidence in Vivani Medical
TipRanks · 01/29 02:01
Vivani Medical Director and 10% Owner Gregg Williams Reports Acquisition of Common Shares
Reuters · 01/28 15:01
Vivani Medical Announces Equity Offerings to Fund Pipeline
TipRanks · 01/27 21:31
Press Release: Vivani Medical, Inc. Announces Closing of Common Stock Offering
Dow Jones · 01/27 21:05
Weekly Report: what happened at VANI last week (0119-0123)?
Weekly Report · 01/26 09:04
Vivani Prices Common Stock Offering At $1.48/Shr
NASDAQ · 01/26 07:40
*Vivani Medical Expects Gross Proceeds of Around $4.5M >VANI
Dow Jones · 01/26 04:40
*Vivani Medical Registered Offering, Private Placement Expected to Close Around Jan. 27 >VANI
Dow Jones · 01/26 04:40
*Vivani Medical Plans to Use Proceeds to Fund Ongoing Research, Clinical Development >VANI
Dow Jones · 01/26 04:40
*Vivani Medical Prices Common Stock Offering >VANI
Dow Jones · 01/26 04:39
VIVANI MEDICAL INC - PRICES DIRECT OFFERING OF 1,689,200 SHARES AT $1.48
Reuters · 01/26 04:36
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
Barchart · 01/25 22:36
Vivani Subsidiary Cortigent To Present Advanced Orion Brain-Implant Technology At NANS 2026, Today
NASDAQ · 01/23 06:54
Vivani subsidiary to present poster on Orion Visual Cortical Prosthesis System
TipRanks · 01/22 12:18
More
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.